Moreover, corticosteroids alleviate LPS‐induced inflammation and lung injury by blocking the activation of NLRP3 inflammasome,46 highlighting that NLRP3 inflammasome can be a drug target for COPD treatment and involves the pathogenesis of COPD, particularly those induced by infection. The gene discussed is NLRP3; the disease is chronic obstructive pulmonary disease.